1. Institut für Klinische & Experimentelle Pharmakologie & Toxikologie, Universität Tübingen, Germany;
2. Adriaens Consulting BVBA, Aalter, Belgium;
3. Bayer Schering Pharma AG, GDD-Global Early Development, Special Toxicology, Wuppertal, Germany;
4. Institute for Health and Consumer Protection, In Vitro Methods Unit/ECVAM, Joint Research Centre, Ispra, Italy;
5. Bayer Crop Science AG, Monheim, Germany;
6. BASF Aktiengesellschaft, Ludwigshafen, Germany;
7. National Institute of Health and the Environment, Laboratory for Health Effects, RIVM, Bilthoven, The Netherlands;
8. evaTox Consulting, Haag, Germany;
9. Vrije Universiteit Brussel, Brussels, Belgium;
10. Axiogenesis AG, Köln, Germany;
11. Federal Institute for Risk Assessment, Center for Alternative Methods to Animal Experiments (ZEBET), Berlin, Germany;
12. Johnson & Johnson Research and Development, Mechanistic Toxicology, Beerse, Belgium;
13. Pfizer Global Research Development, Groton, CT, USA;
14. Altoxicon BVBA, Vosselaar, Belgium;
15. Noscira SA, Tres Cantos, Madrid, Spain;
16. TNO, Zeist, The Netherlands;
17. Schering Plough, Department of Toxicology and Drug Disposition, Oss, The Netherlands;
18. Zentrale Einheit Biostatistik, Deutsches Krebsforschungszentrum, Heidelberg, Germany